Literature DB >> 12006705

Functional IL-18 Is produced by primary pancreatic mouse islets and NIT-1 beta cells and participates in the progression towards destructive insulitis.

Simona Frigerio1, Georg A Holländer, Urs Zumsteg.   

Abstract

BACKGROUND: Preclinical stages of type 1 diabetes are characterized by infiltrating T cells and by the peri- and intra-islet accumulation of pro-inflammatory mediators, such as IFNgamma. METHODS/
RESULTS: Using quantitative PCR we demonstrated that mRNA specific for the IFNgamma-inducing cytokine IL-18 is upregulated in NIT-1 beta cells and intact mouse islets upon exposure to IL-1beta, IFNgamma and TNFalpha. The biological activity of IL-18 was blocked using caspase inhibitors and anti-IL-18 antibodies. Increased IL-18 expression was also detected in islets during advanced stages of insulitis and correlated with elevated transcripts for IFNgamma and for the IL-18 receptor.
CONCLUSION: Thus, beta cells produce bioactive IL-18 in the course of insulitis and actively contribute to the exacerbation of inflammation leading to their own demise. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12006705     DOI: 10.1159/000057959

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  12 in total

1.  IL-18 is required for self-reactive T cell expansion in NOD mice.

Authors:  Annette M Marleau; Nora E Sarvetnick
Journal:  J Autoimmun       Date:  2011-03-16       Impact factor: 7.094

Review 2.  Genetic polymorphisms of cytokine genes in type 2 diabetes mellitus.

Authors:  Monisha Banerjee; Madhukar Saxena
Journal:  World J Diabetes       Date:  2014-08-15

3.  Increased expression of IL-18 in the serum and islets of type 1 diabetics.

Authors:  Robert Z Harms; Danielle N Yarde; Zachary Guinn; Kristina M Lorenzo-Arteaga; Kevin P Corley; Monina S Cabrera; Nora E Sarvetnick
Journal:  Mol Immunol       Date:  2015-01-07       Impact factor: 4.407

4.  Responses of IL-18- and IL-18 receptor-deficient pancreatic islets with convergence of positive and negative signals for the IL-18 receptor.

Authors:  Eli C Lewis; Charles A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

Review 5.  IL-18 in inflammatory and autoimmune disease.

Authors:  Saikiran K Sedimbi; Thomas Hägglöf; Mikael C I Karlsson
Journal:  Cell Mol Life Sci       Date:  2013-07-27       Impact factor: 9.261

6.  Adiponectin blocks interleukin-18-mediated endothelial cell death via APPL1-dependent AMP-activated protein kinase (AMPK) activation and IKK/NF-kappaB/PTEN suppression.

Authors:  Bysani Chandrasekar; William H Boylston; Kaliyamurthi Venkatachalam; Nicholas J G Webster; Sumanth D Prabhu; Anthony J Valente
Journal:  J Biol Chem       Date:  2008-07-15       Impact factor: 5.157

7.  Association of the interleukin-18 -137 C/G, -607 A/C polymorphisms with type 1 diabetes: A meta-analysis.

Authors:  Jing Li; Song Wu; Ming-Rui Wang; Ting-Ting Wang; Bai-Kun Li; Ji-Min Zhu
Journal:  Biomed Rep       Date:  2013-10-23

8.  RIG-I- and MDA5-initiated innate immunity linked with adaptive immunity accelerates beta-cell death in fulminant type 1 diabetes.

Authors:  Kaoru Aida; Yoriko Nishida; Shoichiro Tanaka; Taro Maruyama; Akira Shimada; Takuya Awata; Masako Suzuki; Hiroki Shimura; Soichi Takizawa; Masashi Ichijo; Daiichiro Akiyama; Fumihiko Furuya; Akio Kawaguchi; Masahiro Kaneshige; Jun Itakura; Hideki Fujii; Toyoshi Endo; Tetsuro Kobayashi
Journal:  Diabetes       Date:  2011-02-02       Impact factor: 9.461

9.  Per os colchicine administration in cholesterol fed rabbits: Triglycerides lowering effects without affecting atherosclerosis progress.

Authors:  Vaios Vasileios Kaminiotis; George Agrogiannis; Panagiotis Konstantopoulos; Vasiliki Androutsopoulou; Laskarina Maria Korou; Ioannis S Vlachos; Ismene A Dontas; Despina Perrea; Dimitrios C Iliopoulos
Journal:  Lipids Health Dis       Date:  2017-09-26       Impact factor: 3.876

10.  Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof.

Authors:  Enrique Z Fisman; Michael Motro; Alexander Tenenbaum
Journal:  Cardiovasc Diabetol       Date:  2003-09-12       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.